[go: up one dir, main page]

PE20090968A1 - COMPOUNDS TO INHIBIT THE ACTIVITY OF KSP KINESINA - Google Patents

COMPOUNDS TO INHIBIT THE ACTIVITY OF KSP KINESINA

Info

Publication number
PE20090968A1
PE20090968A1 PE2008001777A PE2008001777A PE20090968A1 PE 20090968 A1 PE20090968 A1 PE 20090968A1 PE 2008001777 A PE2008001777 A PE 2008001777A PE 2008001777 A PE2008001777 A PE 2008001777A PE 20090968 A1 PE20090968 A1 PE 20090968A1
Authority
PE
Peru
Prior art keywords
alkyl
ksp
compounds
cycloalkyl
alkenyl
Prior art date
Application number
PE2008001777A
Other languages
Spanish (es)
Inventor
M Arshad Siddiqui
Chaoyang Dai
Umar Faruk Mansoor
Liping Yang
Lalalnthi Dilrukshi Vitharana
Angie R Angeles
Jr Gerald W Shipps
Xiaohua Huang
Cliff C Cheng
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40254344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of PE20090968A1 publication Critical patent/PE20090968A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE p ES 0-4; ANILLO A ES HETEROCICLOALQUENILO DE 4-8 MIEMBROS; E ES -O-, -S(O)-, NH, -CH2-, ENTRE OTROS; ANILLO B ES DE PREFERENCIA BENZO SUSTITUIDO O NO, TIOFENILO SUSTITUIDO O NO, ENTRE OTROS; R1 ES ARILO, HETEROARILO, CICLOALQUILO, ENTRE OTROS; R2 ES ARILO, -C(O)ALQUILO, COCH3, CICLOALQUILO, ENTRE OTROS; R27 ES H, ALQUILO, ALQUENILO, ARILO, CICLOALQUENILO, ENTRE OTROS; R28 ES H ,ALQUILO, ALQUENILO, HETEROALQUENILO, CICLOALQUILO, ENTRE OTROS; R3 ES ALQUILO, ALQUENILO, HETEROALQUINILO, HETEROCICLOALQUILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES A. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA QUINESINA DEL HUSO (KSP) UTILES EN EL TRATAMIENTO DE CANCERREFERS TO A COMPOUND OF FORMULA I, WHERE p IS 0-4; RING A IS 4-8 MEMBER HETEROCYCLOALKENYL; E IS -O-, -S (O) -, NH, -CH2-, AMONG OTHERS; RING B IS PREFERRED BENZO SUBSTITUTED OR NOT, THIOPHENYL SUBSTITUTED OR NOT, AMONG OTHERS; R1 IS ARYL, HETEROARYL, CYCLOALKYL, AMONG OTHERS; R2 IS ARYL, -C (O) ALKYL, COCH3, CYCLOALKYL, AMONG OTHERS; R27 IS H, ALKYL, ALKENYL, ARYL, CYCLOALKENYL, AMONG OTHERS; R28 IS H, ALKYL, ALKENYL, HETEROALKENYL, CYCLOALKYL, AMONG OTHERS; R3 IS ALKYL, ALKENYL, HETEROALKINYL, HETEROCYCLOALKYL, AMONG OTHERS. A PREFERRED COMPOUND IS A. SUCH COMPOUNDS ARE INHIBITORS OF SPINDLE PROTEIN KINESIN (KSP) USEFUL IN THE TREATMENT OF CANCER

PE2008001777A 2007-11-09 2008-10-16 COMPOUNDS TO INHIBIT THE ACTIVITY OF KSP KINESINA PE20090968A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98679907P 2007-11-09 2007-11-09

Publications (1)

Publication Number Publication Date
PE20090968A1 true PE20090968A1 (en) 2009-07-13

Family

ID=40254344

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001777A PE20090968A1 (en) 2007-11-09 2008-10-16 COMPOUNDS TO INHIBIT THE ACTIVITY OF KSP KINESINA

Country Status (14)

Country Link
EP (1) EP2215064A1 (en)
JP (1) JP2011503076A (en)
KR (1) KR20100075508A (en)
CN (1) CN101952255A (en)
AR (1) AR068889A1 (en)
AU (1) AU2008325025A1 (en)
CA (1) CA2702990A1 (en)
CL (1) CL2008003062A1 (en)
IL (1) IL205181A0 (en)
MX (1) MX2010004314A (en)
PE (1) PE20090968A1 (en)
TW (1) TW200922559A (en)
WO (1) WO2009061596A1 (en)
ZA (1) ZA201002700B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010004312A (en) * 2007-10-19 2010-07-05 Schering Corp Spiro-condensed 1, 3, 4-thiadiazole derivatives for inhibiting ksp kinesin activity.
DE102008001932A1 (en) * 2008-05-21 2009-11-26 Bayer Cropscience Ag Substituted spiroisoxazolines
RU2021101430A (en) * 2014-03-20 2021-03-16 Капелла Терапьютикс, Инк. BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR CANCER TREATMENT
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5336470B2 (en) * 1971-08-09 1978-10-03
ATE448207T1 (en) * 2002-03-08 2009-11-15 Merck & Co Inc MITOTIC KINESIN INHIBITORS
US7449486B2 (en) * 2004-10-19 2008-11-11 Array Biopharma Inc. Mitotic kinesin inhibitors and methods of use thereof
EP1868601A4 (en) * 2005-04-07 2008-12-10 Merck & Co Inc INHIBITORS OF MITOTIC KINESIN

Also Published As

Publication number Publication date
JP2011503076A (en) 2011-01-27
WO2009061596A1 (en) 2009-05-14
ZA201002700B (en) 2010-12-29
TW200922559A (en) 2009-06-01
CN101952255A (en) 2011-01-19
MX2010004314A (en) 2010-04-30
CL2008003062A1 (en) 2010-02-19
AU2008325025A1 (en) 2009-05-14
EP2215064A1 (en) 2010-08-11
IL205181A0 (en) 2010-11-30
CA2702990A1 (en) 2009-05-14
AR068889A1 (en) 2009-12-16
KR20100075508A (en) 2010-07-02

Similar Documents

Publication Publication Date Title
PE20210163A1 (en) NEW PYRIDOPYRIMIDINONES REPLACED WITH BENZYLAMINE AND DERIVATIVES AS SOS INHIBITORS1
PE20141678A1 (en) INDAZOL-3-CARBOXAMIDES AND THEIR USE AS INHIBITORS OF THE WNT / B-CATENIN SIGNALING PATHWAY
PE20070321A1 (en) HETEROCYCLIC COMPOUNDS AS PROTEASE INHIBITORS
EA201690153A1 (en) SUBSTITUTED PETROPHORANE AND BENZOXAZOLYL COMPOUNDS AND THEIR APPLICATIONS
PE20090042A1 (en) CYCLOPAMINE ANALOGS
GT200300296A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
CR11620A (en) Derivatives of Imadazo- [1,2, b] -Piridazine for the Treatment of Tyrosine C-Met Tyrosine-mediated Disease
PE20091349A1 (en) COMPOUNDS DERIVED FROM SPIRO 1,3,4-TIADIAZOL AS INHIBITORS OF KSP KINESINE ACTIVITY
PE20142461A1 (en) ESTROGEN RECEPTOR MODULATORS AND THEIR USES
GT200500225A (en) ENANTIOMERALLY PURE AMINOHETEROARILO COMPOUNDS AS PROTEIN QUINASE INHIBITORS
AR083849A1 (en) ESPIRO-OXINDOL MDM2 ANTAGONISTS
MX2011010451A (en) DERIVATIVES OF OXADIAZOL.
GT200300285A (en) NEW ENANTIOMERS (R) AND (S) OF HYDROXAMIC THIOPHEN ACID DERIVATIVES
PE20110150A1 (en) AMIDOPHENOXYNDAZOLES AS C-MET INHIBITORS
ECSP11010880A (en) ORGANIC COMPOUNDS
ECSP11011244A (en) NEW HERBICIDES.
GT200500242A (en) PROCESSES FOR THE PREPARATION OF 2- (2,6-DIOXOPIPERIDIN-3-IL) -1-SUBSTITUTED OXOISOINDOLINES
MX2015008993A (en) RADIOPHARMACEUTICS AND RADIO-FORMATION AGENTS OF TRIAZINE-BASED IMAGE.
CO6700837A2 (en) Processing process for prrimidine derivatives
UY28700A1 (en) COMPOUNDS
MA35086B1 (en) Compound of triazolopyridine
DOP2010000022A (en) PIRIMIDINE DERIVATIVES 934
EA201170997A1 (en) INDOL DERIVATIVES AS ANTI-TREATMENT AGENTS
UY32004A (en) DERIVATIVES OF CARBAMATOS DE ALQUILTIAZOLES, ITS PREPARATION AND ITS APPLICATION IN THERAPEUTICS
PE20090968A1 (en) COMPOUNDS TO INHIBIT THE ACTIVITY OF KSP KINESINA

Legal Events

Date Code Title Description
FD Application declared void or lapsed